References in New and emerging targeted treatments in advanced non-small-cell lung cancer - The Lancet
The emerging treatment landscape of targeted therapy in non-small-cell lung cancer | Signal Transduction and Targeted Therapy
Targeted therapy for non-small cell lung cancer: current standards and the promise of the future - Chan - Translational Lung Cancer Research
Targeting MET in Lung Cancer: Will Expectations Finally Be MET? - ScienceDirect
Biomarkers in Lung Cancer: Integration with Radiogenomics Data | IntechOpen
Molecular testing for advanced non-small cell lung cancer in Malaysia: Consensus statement from the College of Pathologists, Academy of Medicine Malaysia, the Malaysian Thoracic Society, and the Malaysian Oncological Society - Lung
Diagnosis and Discussion -- Case 1068
Frontiers | Beyond Conventional: The New Horizon of Targeted Therapy for the Treatment of Advanced Non Small Cell Lung Cancer | Oncology
Targeting Infrequent Driver Alterations in Non-Small Cell Lung Cancer: Trends in Cancer
Mutation-tailored treatment selection in non-small cell lung cancer patients in daily clinical practice - Lung Cancer
Biomarker Testing | Lung Cancer Initiative
Cancers | Free Full-Text | Current Molecular-Targeted Therapies in NSCLC and Their Mechanism of Resistance | HTML
Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer - Lung Cancer
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer | Journal of Hematology & Oncology | Full Text
Lung cancer with MET exon 14 skipping mutation | LCTT
MET Signaling: Novel Targeted Inhibition and Its Clinical Development in Lung Cancer - Journal of Thoracic Oncology
Targeting the MET Pathway for Lung Cancer Treatments, Biomarkers
Immunotherapy in non-small cell lung cancer harbouring driver mutations - Cancer Treatment Reviews
Amivantamab: A Potent Novel EGFR/c-MET Bispecific Antibody Therapy for EGFR-mutated Non-small Cell Lung Cancer - touchONCOLOGY
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer | Journal of Hematology & Oncology | Full Text
Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro - Journal of Thoracic Oncology
MET Exon 14 Skipping Alterations in NSCLC: Current Understanding and Therapeutic Advances - touchONCOLOGY
Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations | NEJM
Molecular Diagnostic Assays and Clinicopathologic Implications of MET Exon 14 Skipping Mutation in Non–small-cell Lung Cancer - Clinical Lung Cancer
MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregula | OTT
